Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

The immune system plays a significant role in multiple sclerosis. While MS was historically thought to be T cell-mediated, multiple pieces of evidence now support the view that B cells are essential players in multiple sclerosis pathogenic processes. High-efficacy disease-modifying therapies that ta...

Full description

Bibliographic Details
Main Authors: Jérôme de Sèze, Elisabeth Maillart, Antoine Gueguen, David A. Laplaud, Laure Michel, Eric Thouvenot, Hélène Zephir, Luc Zimmer, Damien Biotti, Roland Liblau
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
rituximab
ocrelizumab
ofatumumab
ublituximab
anti-CD20
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1004795/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1004795/full

Similar Items